吉利德(GILD.US)Q3新冠藥物銷售額大超預期 再次上調全年業績指引
智通財經APP獲悉,$吉利德科學(GILD.US)$第三季度營收爲70.4億美元,遠高於市場預期的61.2億美元;扣除部分項目後的每股收益爲1.90美元,超過市場預期的1.43美元。新冠病例的增加刺激了對Veklury藥物的需求,從而提振了公司的業績。
吉利德在三個月內第二次上調了全年業績指引。公司將產品銷售總額預期從245-250億美元上調至259-262億美元。大部分增長歸因於更高的Veklury銷售額。
Veklury第三季度的銷售額爲9.25億美元,幾乎是市場預期的三倍。吉利德首席執行官Daniel O 'Day週四表示,“我們的銷售額和新冠發病率和流行程度之間有直接的關聯。”該藥物近三分之二的銷售額來自美國以外地區。
雖然Veklury最近的表現超過了預期,但公司長期增長將更多地依賴於核心抗病毒專利和新型抗癌藥物。該公司最大的抗艾滋病藥物Biktarvy在第三季度的銷售額爲27.7億美元,高於市場預期的26億美元。
吉利德科學週四美股盤後漲2.56%,報72美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.